公卫人

 找回密码
 立即注册

QQ登录

只需一步,快速开始

查看: 6254|回复: 3

[分享] Clinical Trial Methodology (2010)

[复制链接]
sampson2010 发表于 2015-5-29 12:42:00 | 显示全部楼层 |阅读模式

注册后推荐绑定QQ,之后方才可以使用下方的“用QQ帐号登录”。

您需要 登录 才可以下载或查看,没有账号?立即注册

x
61yEAoXGxnL.jpg " c% ]( `1 i  H6 R5 z
/ s& Y& h& o' B0 C( Y5 K
Title: Clinical Trial Methodology" e9 B( Z: X  z( ^" Y; Z
Author(s): Karl E. Peace, Din Chen
7 X# k7 _! U; h3 u# USeries: Biostatistics Series        - \0 H9 i7 P# h
Publisher: Chapman & Hall CRC9 G7 u2 T- ]- j0 S' U& }
Year: 2010       
" A( ^( W( S# Y# y# }7 O6 @Edition: 1
0 W! A: D) G( K. Z6 Y- |Language: English
; |3 K: x8 y, G3 l+ A3 ?5 KPages: 420" k9 c$ U+ b! d, k# C! p# Z( J" W
ISBN: 1584889179, 9781584889175, 1584889187, 9781584889182' R+ ~6 Z5 g$ Z9 E
Size: 3 MB (2647392 bytes)3 I; D; F; \  v0 N
Extension: pdf
! w+ @: ]$ {0 i4 z

& ?+ M. V2 I: r( @
4 j2 z( h4 [2 X! QFeatures& Q1 N/ s& u' ~  G3 s

' |2 h0 v7 z. @% s
  • Reviews legislation pertinent to the clinical development of drugs
  • Discusses the processes of drug research and development within the context of a typical pharmaceutical company
  • Presents general biostatistical principles of clinical trials, including protocol development and statistical analysis plan development
  • Provides case studies of clinical trials for the development of drugs to treat panic attacks, duodenal ulcers, and Alzheimer’s disease; to reduce coronary heart disease risk; and to prevent gastric ulcers and angina
    " W% W! Y+ g7 x1 u/ F' g

$ m+ H' `9 v3 H% y3 |" I! y$ t0 R4 y+ x! c4 ]! M3 r! Y, K5 d6 C/ L( e

3 b7 D( w0 P% t5 t7 _$ |) wSummary
# U: S* F! M5 }( B4 T0 s
9 v( v" x* P/ M7 t$ hNow viewed as its own scientific discipline, clinical trial methodology encompasses the methods required for the protection of participants in a clinical trial and the methods necessary to provide a valid inference about the objective of the trial. Drawing from the authors’ courses on the subject as well as the first author’s more than 30 years working in the pharmaceutical industry, Clinical Trial Methodology emphasizes the importance of statistical thinking in clinical research and presents the methodology as a key component of clinical research.& W8 F  F) K, G. C$ y

/ x% p* p2 I$ nFrom ethical issues and sample size considerations to adaptive design procedures and statistical analysis, the book first covers the methodology that spans every clinical trial regardless of the area of application. Crucial to the generic drug industry, bioequivalence clinical trials are then discussed. The authors describe a parallel bioequivalence clinical trial of six formulations incorporating group sequential procedures that permit sample size re-estimation. The final chapters incorporate real-world case studies of clinical trials from the authors’ own experiences. These examples include a landmark Phase III clinical trial involving the treatment of duodenal ulcers and Phase III clinical trials that contributed to the first drug approved for the treatment of Alzheimer’s disease.
/ V6 L" \* z$ x4 c# T% V, d1 a/ o" ~7 E
Aided by the U.S. FDA, the U.S. National Institutes of Health, the pharmaceutical industry, and academia, the area of clinical trial methodology has evolved over the last six decades into a scientific discipline. This guide explores the processes essential for developing and conducting a quality clinical trial protocol and providing quality data collection, biostatistical analyses, and a clinical study report, all while maintaining the highest standards of ethics and excellence.  P/ Z: u" N' a( n

2 {( f: M$ v& ?
: s% j& T( ~9 v* O, k0 [: ~" ]8 R/ O0 {0 X7 c6 P, t  Z9 E) ?
Table of Contents- n) Z0 J+ T8 y
# M" ], E- t8 {1 J4 t- [- o. N) v
Overview of Clinical Trial Methodology
8 |. v5 _- [$ s; G( w$ @# sClinical Trials
$ c6 f* j& J9 Q9 TClinical Trial Methodology
: ^2 F# w- {" K) o, FSummary of Clinical Trial Methodology2 _* u; ~. }! t) p2 L
/ O, v% A( F: X: r2 w3 O* x
Overview of the Drug Development Process and Regulation of Clinical Trials
- U. \7 S" ^+ b) a. a* m1 bIntroduction/ N6 ?$ p# C: g  Y
The Drug Development Process
9 a4 D( H: Q" z2 k8 v/ XHistory of Drug Regulation
7 z' g3 L: A% `3 D( |4 APrinciples of Adequate and Controlled Investigations
! Q" z8 ^" K; x* TContent and Format of the IND' e0 j/ z, q# v' z
Content and Format of the NDA
. L$ |7 x' V! ^2 q# GOrganizational Structure of the FDA
$ F8 J  b3 x8 _1 O2 |' o" iThe FDA Review Process 3 a: d) g9 z4 A0 x8 l0 A8 B
Labeling and the Package Insert ( I  ]0 f4 K# S: y$ |, y
Pharmaceutical Company Organization and Role of the Biostatistician) z' T9 _6 m8 ~; N8 T5 Y

) M/ T' k/ W7 L+ UEthical Considerations in the Design and Conduct of Clinical Trials - [" \7 M6 F- V2 ~' c* }: b' s( R: P5 Z
Introduction
- J+ A, Z2 }. f: @$ }History and Evolution of Ethical Considerations in Clinical Trials: Key Milestones4 g7 z) X; t' N) b% N
Independent Review Boards6 {5 e7 X* Y% ]( J# r% x# X3 v/ d
Clinical Trial Ethics: Who Should Practice?" Q% l1 \6 G* b/ p5 I
Informed Consent, Sample Size, and Power
* U* x/ b1 i+ ~8 _7 ?Common Ethical Principles of Various Codes and Regulations3 _: y% l1 G: S. d$ C! i

1 q# J  U9 o4 p: u  L/ e* l5 aSample Size Considerations in Clinical Trials Pre-Market Approval
0 a8 N+ i; _# u5 ^Introduction: f+ ]: I5 u( A* T' H
Phases of Clinical Trials and Objectives
( r. Y$ m- z  O( O* fThe Clinical Development Plan: Pre-Market Approval
2 ]' N0 |3 t0 C, ~9 o& e6 A* j! PSample Size Requirements- m! {; m1 h+ ]4 a& k# H' s! i" f6 p
Examples
* I# v/ n, @6 @/ S* [- R: T1 |Philosophical Issues
, E9 |6 N9 Z) _' o. V( b8 r" c, B* O( \
Sequential, Group Sequential, Stochastic Curtailment, and Adaptive Design Procedures in Clinical Trials
. c  F8 K0 M9 r- R( [& h& p1 P+ L# JIntroduction
2 H& |8 e. O1 x$ D' @6 LSequential Procedures
" v3 e; ~& H3 _; j6 A6 o9 g  FGroup Sequential Procedures) e2 J0 x! c- Z5 X  m
Stochastic Curtailment) Y; x" c/ ~6 W( L$ t: }" U
Adaptively Designed Clinical Trials
" z5 D1 C* {) z9 Y! o8 d0 x, Q) O, v) J
Biostatistical Aspects of the Protocol $ M6 E; R2 \1 {
The Background or Rationale
5 R* l4 z3 l0 u, M% [% zObjective
) h- ?8 c9 w+ ePlan of Study
- M; a* [& G! K0 _$ ?Statistical Analysis Section
' m7 j  W, L7 ~; ]5 MAdministration. N0 z. {0 I  J) s# p( e$ J
Protocol References Section
& J) i7 j7 l1 D6 w0 L# v, X& v
0 d( {3 U$ s% Y/ zThe Statistical Analysis Plan
7 b7 U0 v' D! _3 U3 u) s  n0 RIntroduction2 N  K5 R8 ^  V( y# `0 ^& \
Protocol Objective
: _+ T3 e) }- dEfficacy Data Collected and Protocol Schema
* W5 u) R: V+ f1 tPrimary and Secondary Efficacy Endpoints- Z: E  S; Z0 K
Objectives, Translated as Statistical Hypotheses* M3 A" t* k% \- Y( q& a* ]7 J; f4 _
Protocol Design Features( Z6 I4 j( x! a9 h' q
Statistical Analyses$ A, b( C4 d$ E1 f5 s( M& J
& T% {, U2 d  z3 Z
Pooling of Data from Multicenter Clinical Trials( K: j; Y( l, @
Introduction
' c/ I' c) M! ]' y+ zMulticenter Clinical Trial Experimental Setting 0 m+ n# T; C# g5 N2 g! t
Pre-Study Planning / _; q+ Z' ]+ K! K- y
Multicenter Clinical Trial Conduct
3 B9 n7 A: k5 N# X/ q( ^Biostatistical Analysis) ^7 `9 Q+ K; ^3 Q; G

! K; |/ t3 t9 k9 S5 \Validity of Statistical Inference9 U! M# X6 R/ G% w* g! w6 }
Introduction
5 Y- h1 S9 s6 z5 X  ePlanning the Investigation
9 E5 X; K, U" `6 Z0 i4 R+ x. qConducting the Investigation & O. A  q+ {% d) J9 C6 p" j
Statistical Analyses, Interpretation, and Inference
- ^5 q; i/ u& O3 q* B. T6 b0 wReporting Results of Investigations
& a) `' o: d7 e8 J3 n; Y5 g
- G+ F' v- p3 E+ C# LBioequivalence Clinical Trials # ?$ D2 Q6 E; f. y: B6 j: q
Introduction
, B1 ]5 J: B' M) O* m9 U* wAbsorption, Distribution, Metabolism, and Excretion (ADME) $ E% o2 f: m0 u+ R' e
Bioavailability 0 m9 l& g+ f8 R, M
Factors That Affect Bioavailability
5 f* U! o! Q. \1 wBlood Level Clinical Trials , ^, \2 i4 Y0 x; |3 ?# Q$ J
Bioequivalence
" H3 G0 k0 }, w9 h( y; u, @% a6 xDesign of Bioequivalence Trials( Y% _) i+ f+ q4 L9 z$ u  D
Analysis of Bioequivalence Trials
: p7 q: C4 {" x/ xAnalysis of Ratios% [7 t+ d/ l- ^+ h/ e$ w5 m
Pharmacokinetic Models
" W: I: C4 Y: r, \; `Support of Bioequivalence Trials in the Pharmaceutical Industry 6 l% v; n4 j8 m, P7 t, m& C2 |
Examples- [7 G# H" \8 R, `
+ x% u% d. S' I" t7 [
Dose and Frequency Determination from Phase II Clinical Trials in Stress Test-Induced Angina
8 e$ U+ n6 Y2 I9 |2 j" d& Y3 k$ BIntroduction
' P! Z3 F0 y; C9 T% E5 S# E0 eOverview of Response Surface Methodology
- X' n0 C% }8 t! g, v5 S8 JFull Quadratic Response Surface Model+ ]& W' u/ {2 E# o& n. |
Phase II Clinical Trial Program in Stress Test-Induced Angina) x* O( T( E8 h" K2 P5 o7 f: L8 C: s
0 }; V# |" b. a+ Z: `7 I
Confirmation of Clinically Optimal Dosing in the Treatment of Duodenal Ulcers: A Phase III Dose Comparison Trial . _/ G" P4 r: u1 q5 \/ o
Introduction3 S5 B& j# K( Y% ]- T  q
Background # Z% W! T8 h1 o1 t8 {9 E* R- [% T
Objective / G8 L- A5 s" w# A" N2 l
Designing and Planning the Investigation  Y0 P# N9 i4 D
Conducting the Investigation / K4 r, _/ l* ~7 @; j0 r
Statistical Analyses7 A2 h9 q6 a$ V0 s9 ~3 S* K# c) m
Other Considerations6 t. @4 Y3 S$ p( E# r6 w
Innovative Aspects of the Clinical Trial Program
" ^1 S! u  p$ H; B4 M7 S1 P
9 m4 u' g& |( M# M, n7 QPivotal Proof-of-Efficacy Clinical Trials in the Prevention of NANSAID-Induced Gastric Ulceration
6 B. r3 h/ i; ^7 tIntroduction2 B6 K% _) Q# f8 x& }2 E9 I
Rationale
4 T2 I. o' P# S. g* i! @The Protocols! ^6 r0 e% k) H$ e" W$ P# i' S" X
Monitoring and Data Management1 d, G1 @! _5 E- A3 ~% ^& b% C
FDA Meeting6 J9 ?& A/ x. \  j  w, R2 q* j

2 E* ^: }, w  c% F, KClinical Trials in the Treatment of Alzheimer’s Disease Based upon Enrichment Designs8 O: ~0 T' h( w# U2 u
Introduction* M) P. k& z! U
Enrichment Design Clinical Trials / U$ @1 ?% \# M2 T0 E$ x: Y6 x
Objective
+ ], P3 L( J- B% `  VPrimary Efficacy Endpoints ! w* b% Y0 N: [; h1 F
Sample Size Determination
; t& i+ j% _0 d0 e3 TStatistical Methods9 K3 r* T) b$ O9 ^' Q
Results
4 n) b! ~. a# G& F! k! |$ m( l4 \8 ?6 j" |
A Clinical Trial to Establish Reduction of CHD Risk
6 x# l& _7 o1 T- d& M, y1 t7 ^& mIntroduction  A; U; p) q0 Y1 y
Objective
  }4 ~$ s+ {# Q: K4 i, vDesigning and Planning the Investigation + Q& `* o# |) ?' s0 R
Conducting the Investigation 0 A/ o& P, [  ?: \/ x& {1 K
Data Management
! G! q, B, ?% gStatistical Analyses
  s% E6 h0 t! {Results8 c5 \2 }1 C0 R+ ~! ]
Summary
  H# |9 j  `$ C: g
' {5 O- q" m1 j/ J/ Y' cPivotal Proof-of-Efficacy Clinical Trials in the Treatment of Panic Disorder
5 g9 H" p9 G# |1 I) ~Introduction! x9 Y" U8 ?" G8 N
Design of Pivotal Proof-of-Efficacy Trials& V- F2 U- E. H; J" Z8 s
Traditional Statistical Analysis Methods 8 C, y! g* x3 R2 @# j
Overview of Efficacy Results of the Two Trials : h( ?# U6 O+ {3 J0 c* b* T( Q
Alternative Design and Analysis Strategies
; d# T; H& @/ \8 p( Z. ]8 D' P- A6 q( e' N
Combination Clinical Trials
" l/ f+ V( ^+ f# }4 ^% f1 x  J9 OIntroduction" D6 Z' P+ y) ?2 d
Two-by-Two Factorial Design 0 b( \4 ~1 P2 h; U5 o
Effectiveness of the Combination
6 J- L7 k9 z( y" K# }Contribution of Components to the Effectiveness of the Combination ! I* r  G- a' Y5 ?4 B; P
Factorial Designs in Other Clinical Development Areas
8 w( C' \3 I7 q8 p, nExample 1: Actifed in the Treatment of SAR Following DESI Review
* w- p+ Y9 G' I3 p% uExample 2: Crossover Trial of Actifed in the Treatment of SAR" T. X& Z6 \1 p2 u6 Z$ j
Example 3: Parallel Trial of Actifed in the Treatment of the Common Cold% [: L! A  Z8 E/ [6 O7 m% M

# ~( Z! X) t. ?# }- K( U. `8 IMonitoring Clinical Trials for Adverse Events : I! `$ E" M6 i: v" l4 ]" ?
Introduction) v8 h2 K5 d$ c1 Z, k4 @
Designing for Safety: Antibiotic Rash Example
6 U; n4 I: ]/ \0 Y9 Y: g4 ]Designing for Safety: Hypokalemia Example # u1 v7 N+ A3 `" o4 n  a0 T
Designing for Safety: Hypertensive Rebound Example
+ s1 K; l( W6 z8 c3 g$ r( Z8 V: a+ FPremarket Approval Trials: Designed for Efficacy
; Q2 W6 W- a# Z& h$ EPremarket Approval Trials: Quality of Adverse Event Information. I9 K) @* H2 D# |* t0 [
Monitoring for Safety  t  D' h, B  P* ?
Statistical Methodology: Individual Trial
% v; B' S' c6 i# S7 B/ O! ?Example- v: d4 L' t* u: w
Statistical Methodology: Across Trials
6 I  Q' h6 X" Q
( ^4 Q# P( K! ~+ R) SIndex
( k( E: D! s) Y; O* }& X
; W. c5 s4 N* DReferences appear at the end of each chapter.
4 ?* O( ]* q  J0 C9 D4 x' x/ g: X. P1 G! Y5 d5 N' u; u$ O

" l5 u- s- Y2 P& J: R4 p7 F4 U- I( f" Z
Author(s) Bio) t( \% ^4 c6 h3 E" u6 B

! P0 o5 j8 k" F! O+ M2 kKarl E. Peace is the Georgia Cancer Coalition Distinguished Cancer Scholar, founding director of the Center for Biostatistics, and professor of biostatistics in the Jiann-Ping Hsu College of Public Health at Georgia Southern University.- P! O7 D% C' n( c8 K; I5 s

0 n5 u8 p# X$ g% s* D+ w3 ODin Chen is the Karl E. Peace Endowed Eminent Scholar Chair in Biostatistics and professor of biostatistics in the Jiann-Ping Hsu College of Public Health at Georgia Southern University., @+ _! f- S' f) x) m

/ l+ b* Y8 j0 w- a& J! Z/ T. ?. }& A+ g0 L7 X" ]& o9 B9 t, x

# M  L% Y; I" j2 f4 u Clinical Trial Methodology (2010).pdf (2.52 MB, 下载次数: 100) 1 T+ b0 h, M5 S! T0 t( S, m
( L, m" L/ G6 m# F% E. b
: E  ]2 q4 f, }& `( M6 r
来自群组: RGCE

本帖被以下淘专辑推荐:

tljuly 发表于 2017-12-23 23:08:15 | 显示全部楼层
好书!!多谢分享
回复

使用道具 举报

芬2012 发表于 2018-4-23 14:29:53 | 显示全部楼层
已下载,感谢分享
回复

使用道具 举报

1582891835 发表于 2018-7-26 10:51:39 | 显示全部楼层
多谢楼主分享~
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

手机版|会员|至尊|接种|公卫人 ( 沪ICP备06060850号-3 )

GMT+8, 2024-4-26 02:11 , Processed in 0.061538 second(s), 7 queries , Gzip On, MemCached On.

Powered by Discuz! X3.4

© 2001-2023 Discuz! Team.

快速回复 返回顶部 返回列表